Discovery Chemistry and Candidate Optimization, Bristol Myers Squibb, Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA.
Bioorg Med Chem Lett. 2011 May 15;21(10):2925-9. doi: 10.1016/j.bmcl.2011.03.067. Epub 2011 Mar 23.
Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles that possess multiple additional vectors for further exploration. The binding mode and pharmacokinetic (PK) properties of select examples, including: 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[2,1-d][1,4]benzodiazepine-10-carboxylic acid (7) (IC(50)=0.07 μM, %F=18), are reported.
在此,我们展示了一系列桥连 2-芳基吲哚为基础的 NS5B 抑制剂的初步 SAR 研究。在吲哚 N1 和 2-芳基部分的邻位之间引入桥接元素,导致形成构象受限的杂环,具有多个进一步探索的附加矢量。选择的例子的结合模式和药代动力学(PK)特性,包括:13-环己基-6-氧代-6,7-二氢-5H-吲哚并[2,1-d][1,4]苯并二氮杂 - 10-羧酸(7)(IC(50)= 0.07 μM,%F = 18),被报道。